Divisions of Hematology & Oncology

• Home
• About Us
  • Overview
  • Washington U
  • St. Louis
• People
  • Faculty
  • Fellows
  • Alumni
• Conferences
  • Calendar
  • Hematology Grand Rounds
  • Medical Oncology Grand Rounds
  • Cancer Management Series
  • Clinical Trials Bootcamp
  • Fellows' Journal Club
  • Core Cases in Hematology / Oncology
  • Hematology Research / Work-In-Progress Seminar
  • Cancer Biology Pathway
• Training
  • Hematology-Oncology Fellowship
  • Hematology-Focused Fellowship Training Program
  • K12 Paul Calabresi Career Development Program in Clinical Oncology
  • T32 Training Program in Molecular Hematology
• Research
  • Basic
  • Clinical
  • Developmental Therapeutics
• Patient Care
  • Overview
  • Clinical Protocols
  • Adult Hemophilia and Bleeding Disorders Center
  • Center for Gene and Cellular Immunotherapy

Original Articles

• Final Findings From the CONTROL Trial: Strategies to Reduce the Incidence and Severity of Neratinib-Associated Diarrhea in Patients With HER2-Positive Early-Stage Breast Cancer
  Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, Garcia-Saenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH
  Breast 2023 Feb;67:94-101
• Circulating Tumour DNA Characterisation of Invasive Lobular Carcinoma in Patients With Metastatic Breast Cancer
  Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M
  EBioMedicine 2022 Dec;86:104316
• The Phase II MutHER Study of Neratinib Alone and in Combination With Fulvestrant in HER2-Mutated, Non-Amplified Metastatic Breast Cancer
  Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R
  Clin Cancer Res 2022 Apr 1;28(7):1258-1267
• Cardiac Outcomes of Subjects on Adjuvant Trastuzumab Emtansine Vs Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT) Study (TBCRC033): A Randomized Controlled Trial
  Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM
  NPJ Breast Cancer 2022 Feb 16;8(1):18
• Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy
  Chudnovsky Y, Kumar RD, Schrock AB, Connelly C, Gowen K, Frampton GM, Erlich RL, Stephens PJ, Miller VA, Ross JS, Ali SM, Bose R
  JCO Precis Oncol 2017 Nov;1:1-9
• Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
  Bose R, Ma CX
  N Engl J Med 2021 Sep 23;385(13):1241-1243
• Pertuzumab and Trastuzumab for HER2-Positive, Metastatic Biliary Tract Cancer (MyPathway): A Multicentre, Open-Label, Phase 2a, Multiple Basket Study
  Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H
  Lancet Oncol 2021 Sep;22(9):1290-1300
• Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple-Negative Breast Cancer
  Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M
  Breast Cancer Res Treat 2021 Aug;189(1):187-202
• Chemotherapy-Related Amenorrhea (CRA) After Adjuvant Ado-Trastuzumab Emtansine (T-DM1) Compared to Paclitaxel in Combination With Trastuzumab (TH) (TBCRC033: ATEMPT Trial)
  Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM
  Breast Cancer Res Treat 2021 Aug;189(1):103-110
• Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients With Central Nervous System Involvement From the NALA Trial
  Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcon J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinavar F, Bryce R, Keyvanjah K, Brufsky AM
  Oncologist 2021 Aug;26(8):e1327-e1338
• Neratinib + Capecitabine Sustains Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer and >/= 2 Prior HER2-Directed Regimens
  Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N
  Breast Cancer Res Treat 2021 Jul;188(2):449-458
• The Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With HER2+ and Androgen Receptor-Positive Metastatic or Locally Advanced Breast Cancer
  Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE
  Breast Cancer Res Treat 2021 May;187(1):155-165
• Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
  Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I
  J Clin Oncol 2021 Jul 20;39(21):2375-2385
• HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium
  Murray E, Cheng X, Krishna A, Jin X, Ohara TE, Stappenbeck TS, Bose R
  Cell Mol Gastroenterol Hepatol 2021;12(3):1105-1120
• Mutation Profile Differences in Younger and Older Patients With Advanced Breast Cancer Using Circulating Tumor DNA (CtDNA)
  Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, Opyrchal M, Wildes TM, Ma C
  Breast Cancer Res Treat 2021 Feb;185(3):639-646
• Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor
  Regmi R, Srinivasan S, Latham AP, Kukshal V, Cui W, Zhang B, Bose R, Schlau-Cohen GS
  J Phys Chem Lett 2020 Dec 3;11(23):10037-10044
• Improved Tolerability of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: The CONTROL Trial
  Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A
  CONTROL Study Investigators
  Ann Oncol 2020 Sep;31(9):1223-1230
• Targeted Therapy for Advanced Salivary Gland Carcinoma Based on Molecular Profiling: Results From MyPathway, a Phase IIa Multiple Basket Study
  Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C
  Ann Oncol 2020 Mar;31(3):412-421
• Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials
  Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU
  JCO Precis Oncol 2019 Nov 15;3
• Pertuzumab Plus Trastuzumab for HER2-Amplified Metastatic Colorectal Cancer (MyPathway): An Updated Report From a Multicentre, Open-Label, Phase 2a, Multiple Basket Study
  Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J
  Lancet Oncol 2019 Apr;20(4):518-530
• Imaging of HER2 With [(89)Zr]pertuzumab in Response to T-DM1 Therapy
  Massicano AVF, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE
  Cancer Biother Radiopharm 2019 May;34(4):209-217
• Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
  Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX
  J Natl Compr Canc Netw 2019 Feb;17(2):141-147
• The Prognostic Effects of Somatic Mutations in ER-Positive Breast Cancer
  Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ
  Nat Commun 2018 Sep 4;9(1):3476
• Evaluation of [(89)Zr]trastuzumab-PET/CT in Differentiating HER2-Positive From HER2-Negative Breast Cancer
  Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA
  Breast Cancer Res Treat 2018 Jun;169(3):523-530
• Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
  Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R
  J Clin Oncol 2018 Feb 20;36(6):536-542
• Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy
  Chudnovsky Y, Kumar RD, Schrock AB, Gowen K, Frampton GM, Connelly C, Stephens PJ, Miller VA, Ross JS, Ali SM, Bose R
  JCO Precision Oncology 2017 Aug 1; published online
• Analysis of Somatic Mutations Across the Kinome Reveals Loss-Of-Function Mutations in Multiple Cancer Types
  Kumar RD, Bose R
  Sci Rep 2017 Jul 25;7(1):6418
• Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
  Ma CX*, Bose R*, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC (*co-first authors)
  Clin Cancer Res 2017 Oct 1;23(19):5687-5695
• CIViC Is a Community Knowledgebase for Expert Crowdsourcing the Clinical Interpretation of Variants in Cancer
  Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, Barnell EK, Wagner AH, Skidmore ZL, Wollam A, Liu CJ, Jones MR, Bilski RL, Lesurf R, Feng YY, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Gangavarapu K, Eldred JM, Larson DE, Walker JR, Good BM, Wu C, Su AI, Dienstmann R, Margolin AA, Tamborero D, Lopez-Bigas N, Jones SJ, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL
  Nat Genet 2017 Jan 31;49(2):170-174
• Efficient Sortase-Mediated N-Terminal Labeling of TEV Protease Cleaved Recombinant Proteins
  Sarpong K, Bose R
  Anal Biochem 2017 Mar 15;521:55-58
• Biophysical Evidence for Intrinsic Disorder in the C-Terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases
  Keppel TR, Sarpong K, Murray EM, Monsey J, Zhu J, Bose R
  J Biol Chem 2017 Jan 13;292(2):597-610
• Unsupervised Detection of Cancer Driver Mutations With Parsimony-Guided Learning
  Kumar RD, Swamidass SJ, Bose R
  Nat Genet 2016 Oct;48(10):1288-94
• Neratinib Plus Paclitaxel Vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
  Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA
  JAMA Oncol 2016 Dec 1;2(12):1557-1564
• [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women With HER2-Positive Breast Cancer
  Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F
  Mol Imaging Biol 2016 Dec;18(6):952-959
• Nonamplification ERBB2 Genomic Alterations in 5605 Cases of Recurrent and Metastatic Breast Cancer: An Emerging Opportunity for Anti-HER2 Targeted Therapies
  Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ
  Cancer 2016 Sep 1;122(17):2654-2662
• Genomic Characterization of Primary Invasive Lobular Breast Cancer
  Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothe F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohee S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C
  J Clin Oncol 2016 Jun 1;34(16):1872-81
• HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
  Ben-Baruch NE*, Bose R*, Kavuri SM, Ma CX, Ellis MJ (*co-corresponding authors)
  J Natl Compr Canc Netw 2015 Sep;13(9):1061-4
• Statistically Identifying Tumor Suppressors and Oncogenes From Pan-Cancer Genome-Sequencing Data
  Kumar RD, Searleman AC, Swamidass SJ, Griffith OL, Bose R
  Bioinformatics 2015 Nov 15;31(22):3561-8
• HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
  Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R
  Cancer Discov 2015 Aug;5(8):832-41
• Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor
  Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J
  Mol Cell Biol 2015 Sep 1;35(17):3083-102
• HER2 Missense Mutations Have Distinct Effects on Oncogenic Signaling and Migration
  Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH
  Proc Natl Acad Sci U S A 2015 Nov 10;112(45):E6205-14
• Tissue Phosphoproteomics With PolyMAC Identifies Potential Therapeutic Targets in a Transgenic Mouse Model of HER2 Positive Breast Cancer
  Searleman AC, Iliuk AB, Collier TS, Chodosh LA, Tao WA, Bose R
  Electrophoresis 2014 Apr 10
• DGIdb: Mining the Druggable Genome
  Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, Koval J, Das I, Callaway MB, Eldred JM, Miller CA, Subramanian J, Govindan R, Kumar RD, Bose R, Ding L, Walker JR, Larson DE, Dooling DJ, Smith SM, Ley TJ, Mardis ER, Wilson RK
  Nat Methods 2013 Dec;10(12):1209-10
• Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
  Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ
  Cell Rep 2013 Sep 26;4(6):1116-30
• Carboxyl Group Footprinting Mass Spectrometry and Molecular Dynamics Identify Key Interactions in the HER2-HER3 Receptor Tyrosine Kinase Interface
  Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R
  J Biol Chem 2013 Aug 30;288(35):25254-64
• Prioritizing Potentially Druggable Mutations With DGene: An Annotation Tool for Cancer Genome Sequencing Data
  Kumar RD, Chang LW, Ellis MJ, Bose R
  PLoS One 2013 Jun 27;8(6):e67980
• A Neu View of Invasive Lobular Breast Cancer
  Bose R
  Clin Cancer Res 2013 Jul 1;19(13):3331-3
• Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer
  Goncalves R, Bose R
  J Natl Compr Canc Netw 2013 Feb 1;11(2):174-82; quiz 182
• Incorporating Genomics Into Breast Cancer Clinical Trials and Care
  Tabchy A, Ma CX, Bose R, Ellis MJ
  Clin Cancer Res 2013 Dec 1;19(23):6371-9
• Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
  Bose R*, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ* (*co-corresponding authors)
  Cancer Discov 2013 Feb;3(2):224-37
• Quantitative Proteomics With siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
  Boyer AP, Collier TS, Vidavsky I, Bose R
  Mol Cell Proteomics 2013 Jan;12(1):180-93
• Comprehensive Molecular Portraits of Human Breast Tumours
  The Cancer Genome Atlas Network (authors include Bose R)
  Nature 2012 Sep 23;490(7418):61-70
• Comprehensive Genomic Characterization of Squamous Cell Lung Cancers
  Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M
  Nature 2012 Sep 27;489(7417):519-25
• Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
  Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK
  Cell 2012 Sep 14;150(6):1121-34
• Whole-Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition
  Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
  Nature 2012 Jun 10;486(7403):353-60
• Identification of Targets of c-Src Tyrosine Kinase by Chemical Complementation and Phosphoproteomics
  Ferrando IM, Chaerkady R, Zhong J, Molina H, Jacob HK, Herbst-Robinson K, Dancy BM, Katju V, Bose R, Zhang J, Pandey A, Cole PA
  Mol Cell Proteomics 2012 Aug;11(8):355-69
• Carboxyl-Group Footprinting Maps the Dimerization Interface and Phosphorylation-Induced Conformational Changes of a Membrane-Associated Tyrosine Kinase
  Zhang H, Shen W, Rempel D, Monsey J, Vidavsky I, Gross ML, Bose R
  Mol Cell Proteomics 2011 Jun;10(6):M110005678
• Exome Sequencing and Cis-Regulatory Mapping Identify Mutations in MAK, a Gene Encoding a Regulator of Ciliary Length, as a Cause of Retinitis Pigmentosa
  Ozgul RK, Siemiatkowska AM, Yucel D, Myers CA, Collin RW, Zonneveld MN, Beryozkin A, Banin E, Hoyng CB, van den Born LI, Bose R, Shen W, Sharon D, Cremers FP, Klevering BJ, den Hollander AI, Corbo JC
  Am J Hum Genet 2011 Aug 12;89(2):253-64
• Her4 and Her2/Neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System
  Monsey J, Shen W, Schlesinger P, Bose R
  J Biol Chem 2010 Mar 5;285(10):7035-44
• The ErbB Kinase Domain: Structural Perspectives Into Kinase Activation and Inhibition
  Bose R, Zhang X
  Exp Cell Res 2009 Feb 15;315(4):649-58
• Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase
  Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ
  Structure 2008 Mar;16(3):460-7
• Human Proteinpedia Enables Sharing of Human Protein Data
  Mathivanan S, Ahmed M, Ahn NG, Alexandre H, Amanchy R, Andrews PC, Bader JS, Balgley BM, Bantscheff M, Bennett KL, Bjorling E, Blagoev B, Bose R, et al.
  Nat Biotechnol 2008 Feb;26(2):164-7
• Inhibition of the EGF Receptor by Binding of MIG6 to an Activating Kinase Domain Interface
  Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J
  Nature 2007 Nov 29;450(7170):741-4
• Phosphoproteomic Analysis of Her2/Neu Signaling and Inhibition
  Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, Pandey A, Cole PA
  Proc Natl Acad Sci U S A 2006 Jun 27;103(26):9773-8
• Protein Tyrosine Kinase-Substrate Interactions
  Bose R, Holbert MA, Pickin KA, Cole PA
  Curr Opin Struct Biol 2006 Dec;16(6):668-75
• Measurement of Ceramide Levels by the Diacylglycerol Kinase Reaction and by High-Performance Liquid Chromatography-Fluorescence Spectrometry
  Bose R, Kolesnick R
  Methods Enzymol 2000;322:373-8
• Measurement of Ceramide Synthase Activity
  Bose R, Kolesnick R
  Methods Enzymol 2000;322:378-82
• Ceramide Generation by the Reaper Protein Is Not Blocked by the Caspase Inhibitor, P35
  Bose R, Chen P, Loconti A, Grullich C, Abrams JM, Kolesnick RN
  J Biol Chem 1998 Oct 30;273(44):28852-9
• Autoantibodies to DEK Oncoprotein in a Patient With Systemic Lupus Erythematosus and Sarcoidosis
  Dong X, Michelis MA, Wang J, Bose R, DeLange T, Reeves WH
  Arthritis Rheum 1998 Aug;41(8):1505-10
• Requirement for Ceramide-Initiated SAPK/JNK Signalling in Stress-Induced Apoptosis
  Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN
  Nature 1996 Mar 7;380(6569):75-9
• Ceramide Synthase Mediates Daunorubicin-Induced Apoptosis: An Alternative Mechanism for Generating Death Signals
  Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R
  Cell 1995 Aug 11;82(3):405-14
• Overexpression of SIS2, Which Contains an Extremely Acidic Region, Increases the Expression of SWI4, CLN1 and CLN2 in Sit4 Mutants
  Di Como CJ, Bose R, Arndt KT
  Genetics 1995 Jan;139(1):95-107
• The Genes for a Mouse Hematopoietic Differentiation Marker Called the Heat-Stable Antigen
  Wenger RH, Ayane M, Bose R, Kohler G, Nielsen PJ
  Eur J Immunol 1991 Apr;21(4):1039-46

Invited Publications and Book Chapters

• Breast Cancer
  Clifton K, Ademuyiwa FO, Bose R, Ma CX
  In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 5th Edition (Morgensztern D, Govindan R, Devarakonda S, Trikalinos NA, Editors), Wolters Kluwer, Philadelphia, 2022
• HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer
  Murray EM, Cherian MA, Ma CX, Bose R
  Current Breast Cancer Reports 2018 Jun;10:41
• Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer
  Ma CX, Bose R, Ellis MJ
  Adv Exp Med Biol 2016;882:125-54
• Chapter 19: Genomic Events in Breast Cancer Progression
  Goncalves R, Cakar B, Bose R, Ma CX, Ellis MJ
  In: Diseases of the Breast, 5th edition. Editors: Harris JR, Lippman ME, Morrow M, Osborne CK. Lippincott Williams & Wilkins, Philadelphia. In press
• Target Proteins: Bottom-Up and Top-Down Proteomics
  Boyne MT II, Bose R
  In: Protein and Peptide Mass Spectrometry in Drug Discovery. Editors: Gross ML, Chen G, Pramanik BN. John Wiley & Sons, New Jersey. 2012, pp 89-100
• Colorectal Cancer
  Bose R
  In: The Washington Manual: Hematology and Oncology Subspecialty Consult (G Pillot, ed), Lippincott Williams & Wilkins, Philadelphia, 2004, pp 150-158
• Other Gastrointestinal Malignancies
  Bose R
  In: The Washington Manual: Hematology and Oncology Subspecialty Consult (G Pillot, ed), Lippincott Williams & Wilkins, Philadelphia, 2004, pp 159-165
• Lymphoma
  Bose R
  In: The Washington Manual: Hematology and Oncology Subspecialty Consult (G Pillot, ed), Lippincott Williams & Wilkins, Philadelphia, 2004, pp 221-228

Electronic Publications

• ASCO Tumor Board: HER2 Positive Breast Cancer
  Bose R, Henry NL
  E-published Oct 16, 2013 on elearning.asco.org
• New Drugs for HER2-Positive Metastatic Breast Cancer: Trastuzumab-DM1, Neratinib, and Tanespimycin
  Bose R, Van Tine B
  E-Updates in HER1 and HER2 Targeting in Breast Cancer, Volume 3 (MJ Ellis, ed), electronically published on CancerNetwork.com, Nov 12, 2009
• Advances in Our Understanding of Resistance to Trastuzumab
  Bose R, Van Tine B
  E-Updates in HER1 and HER2 Targeting in Breast Cancer, Volume 3 (MJ Ellis, ed), electronically published on CancerNetwork.com, Nov 12, 2009
• Current and Future Roles of Lapatinib in HER2-Positive Breast Cancer
  Ma C, Bose R
  E-Updates in HER1 and HER2 Targeting in Breast Cancer, Volume 2 (MJ Ellis, ed), electronically published on CancerNetwork.com, Sep 1, 2008